Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX™ Product D...
April 28 2020 - 09:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, announced
today that it has formed a strategic partnership with HydroPeptide,
LLC, a leading epigenetics skin care company, to engage in
co-development and commercialization of a series of clinical-grade,
exosome-based cosmeceutical and orthopedic products.
Product characterization, process development and
bio-manufacturing standardization will be performed at Weill
Cornell Medicine, a cGMP and FACT-accredited facility led by
Principal Investigator, Dr. Yen-Michael Hsu. A three-way
material transfer agreement has been signed and executed by Avalon,
HydroPeptide and Weill Cornell Medicine.
Stem cell-derived Avalon Clinical-grade Tissue-specific
Exosomes (ACTEXTM) is one of the core
technology platforms that has been co-developed by Avalon GloboCare
and Weill Cornell Medicine. This strategic partnership aims
to synergize the technological expertise in skin care technology
and regenerative medicine from both companies, as well as the
acceleration of product commercialization pathways.
“We are thrilled to begin this venture with Avalon Globocare to
create a game-changing technology for our customers. We
believe our combined expertise will deliver a transformational
approach to skin care that will revolutionize the industry,” said
Annette Rubin, CEO of HydroPeptide.
“We are very excited about this strategic partnership with
HydroPeptide, which brings together cutting-edge innovation and
commercialization expertise in skin care and regenerative
medicine,” stated David Jin, M.D., Ph.D., CEO and President of
Avalon GloboCare. “Specifically, we believe this platform has
potential to transform the cosmetic and orthopedic markets, given
the ability of exosomes to promote tissue repair and regeneration,”
added Dr. Jin
About HydroPeptide, LLC
Since 2004, HydroPeptide has revolutionized skin care through
epigenetic science and peptide technology. Their products work at
the cellular level to increase hydration, visibly reduce lines and
wrinkles and enhance skin’s natural luminosity. With a multitude of
peptides, antioxidants, botanical stem cells, growth factors and
hyaluronic acid, their award-winning products and professional
treatments offer, customizable results-driven regimens for all skin
types, wrapped up in a luxurious experience. HydroPeptide is
currently found in the most prestigious spas, medical spas and
physician offices in 35 countries. The company’s unique vision of
epigenetic skin care appeals to the most discerning clients and
retailers with an upscale experience and flawless,
clinically-proven results. For more information, please
visit www.hydropeptide.com.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
vertically-integrated, leading CellTech bio-developer dedicated to
advancing and empowering innovative, transformative immune effector
cell therapy and exosome technology. Avalon also provides strategic
advisory and outsourcing services to facilitate and enhance its
clients' growth, development, as well as competitiveness in
healthcare and CellTech industry markets. Through its
subsidiary structure with unique integration of verticals from
innovative R&D to automated bioproduction and accelerated
clinical development, Avalon is establishing a leading role in the
fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEXTM), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2023 to Mar 2024